Tag: 100-200

On October 15, 1999, Roda, Gabriella; Riva, Sergio; Danieli, Bruno published an article.Name: Isochroman-3-ol The title of the article was Almond oxynitrilase-catalyzed transformation of aldehydes is strongly influenced by naphthyl and alkoxy substituents. And the article contained the following:

Different α- and β-substituted aldehydes have been submitted to the catalytic action of almond oxynitrilase (PaHNL), in order to explore the influence of a stereocenter already present in the substrate on the selectivity of this enzyme. The results indicate that naphthyl and alkoxy substituents in the α- and also in the β-position to the aldehyde group significantly influence the stereochem. outcome of the PaHNL-catalyzed transformation. The experimental process involved the reaction of Isochroman-3-ol(cas: 42900-89-0).Name: Isochroman-3-ol

The Article related to almond oxynitrilase catalyst transformation aldehyde cyanohydrin, cyanohydrin preparation almond oxynitrilase catalyst, Benzene, Its Derivatives, and Condensed Benzenoid Compounds: Aldehydes and Derivatives, Including Sulfur Analogs and other aspects.Name: Isochroman-3-ol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 31, 2013, Wang, Baozong; Wei, Jun; Qiu, Jun published an article.Formula: C8H19NO2 The title of the article was Preparation and properties of polyester-type polymeric thioxanthone photoinitiators. And the article contained the following:

2-(2, 3-Dihydroxy) propoxy-thioxanthone (HPTX), a thioxanthone monomer containing two active hydroxyl groups, was synthesized. Then, through step polymerization of HPTX, hexyl dichloride and N-substituted diethanolamine, polyester-type polymeric photoinitiators containing side-chain thioxanthone and in-chain coinitiator amine were obtained. Moreover, the influences of coinitiator amine structure on the photopolymerization were also studied. FT-IR and 1H-NMR analyses confirm the structures of polymeric photoinitiators. UV-Vis spectra show that the macromol. chain has no obvious effect on the maximal absorption of thioxanthone moieties. Photopolymerization of polyester acrylate resin (PEA), initiated by polyester-type polymeric thioxanthone photoinitiators, was studied through photo differential scanning calorimetry (photo-DSC). The results show that PET-HBTX can effectively initiate the photopolymerization of PEA. The experimental process involved the reaction of 2,2′-(tert-Butylazanediyl)diethanol(cas: 2160-93-2).Formula: C8H19NO2

The Article related to polymeric thioxanthone photoinitiator polyester acrylate polymerization kinetics preparation, Chemistry of Synthetic High Polymers: Polymerization Kinetics, Mechanisms, Thermodynamics, Catalysis, Catalysts and other aspects.Formula: C8H19NO2

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On September 30, 1992, Allen, K. W.; Cockburn, E. S.; Davidson, R. S.; Tranter, K. S.; Zhang, H. S. published an article.Product Details of 2160-93-2 The title of the article was Some new developments in radiation curing. And the article contained the following:

Decomposition of cationic photoinitiators in the solid state is used in a remote cure process i.e. one in which photoinitiator is not present in the polymerizable monomer. An application of this process to a dual cure system is described. Details are given of free radical polymerization reactions of ethylhexyl acrylate in aqueous solutions which produce latexes via both suspension and emulsion polymerization processes. Ways of improving the photosensitivity of poly(vinyl alc.) modified with styrylpyridinium groups utilizing mixed [2+2]cycloaddition reactions are reviewed. The experimental process involved the reaction of 2,2′-(tert-Butylazanediyl)diethanol(cas: 2160-93-2).Product Details of 2160-93-2

The Article related to crosslinking cationic photochem catalyst, polymerization catalyst photochem cationic, Chemistry of Synthetic High Polymers: Polymerization Kinetics, Mechanisms, Thermodynamics, Catalysis, Catalysts and other aspects.Product Details of 2160-93-2

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On June 21, 2012, Surman, Matthew D.; Guzzo, Peter R.; Freeman, Emily; Henderson, Alan J. published a patent.Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of tetrahydro-azacarboline MCH-1 antagonists. And the patent contained the following:

The present invention relates to tetrahydro-azacarboline derivatives I [G = NR8CR9C10 or CR9R10NR8; X = CR16, C(R16)2, N, NR16; Y = CR16, C, N; W = C or N; Q = C or N; Z = C, CH or N; L = (CH2)pO, (CH2)p, CH:CH, a bond; A = C, CH, CH2, N; B = (un)substituted (hetero)aryl, heterocyclyl, cycloalkyl; R1 = H, alkyl, cycloalkyl, etc.; R2-R5, R9-R10 = H, halo, alkyl, etc.; R6 = H, halo, aryl, etc.; R7 = H, halo, CN, etc.; R8 = H, alkyl, cycloalkyl, etc.; n = 0-3; p = 1-4] which are melanin-concentrating hormone (MCH-1) receptor antagonists. Twenty-eight compounds I were prepared E.g., a multi-step synthesis of II.HCl, starting from 2,6-dibromopyridine, was described. Exemplified compounds I were tested in the human MCH-1 binding assay (data given). The present invention also relates to pharmaceutical compositions including these compounds, and methods of preparation and use thereof. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to azacarboline preparation melanin concentrating hormone mch1 receptor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On March 31, 2016, Cai, Jiaqiang; Colandrea, Vincent; Crespo, Alejandro; Debenham, John; Du, Xiaoxing; Guiadeen, Deodialsingh; Liu, Ping; Liu, Rongqiang; Madsen-Duggan, Cristina B.; McCoy, Joshua G.; Quan, Weiguo; Sinz, Christopher; Wang, Liping published a patent.Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Quinolinecarboxamidoacetic acids and related compounds as inhibitors of HIF prolyl hydroxylase and their preparation. And the patent contained the following:

The invention concerns compounds of formula I or pharmaceutically acceptable salts thereof, which inhibit HIF prolyl hydroxylase, their use for enhancing endogenous production of erythropoietin, and for treating conditions associated with reduced endogenous production of erythropoietin such as anemia and like conditions, as well as pharmaceutical compositions comprising such a compound and a pharmaceutical carrier. Compounds of formula I wherein W and Z are independently CH2 and NH and derivatives; X and Y are independently CH2, O, CO and NH and derivatives; provided that when W and Z are CH2, then WZ may be taken together with another carbon to form a bridge; R1 is H, C1-4 alkyl, (un)substituted C3-8 cycloalkyl, (un)substituted aryl, (un)substituted heterocyclyl, etc.; R2 is H and Me; R3 and R4 are independently H, OH and (un)substituted C1-4 alkyl; and pharmaceutically acceptable salts thereof, are claimed. Example compound II was prepared by a multistep procedure (procedure given). The invention compounds were evaluated for their HIF prolyl hydroxylase inhibitory activity. From the assay, it was determined that compound II exhibited IC50 value of 19.2 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to quinolinecarboxamidoacetic acid preparation hif prolyl hydroxylase inhibitor, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Safety of (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On August 30, 2007, Vanotti, Ermes; Martina, Katia; Menichincheri, Maria; D’Alessio, Roberto published a patent.Quality Control of 1-(3-Fluoropyridin-4-yl)ethanol The title of the patent was Preparation of pyrrolopyrrolones as kinase inhibitors for treating cancer and other diseases. And the patent contained the following:

Compounds represented by formula I (wherein A is pyridin-4-yl, 3-fluoropyridin-4-yl, and 2-aminopyrimidin-4-yl; R1 is H, halo, and (C1-C6)alkyl; R2 is H, (C1-C6)alkyl, (C2-C6)alkenyl, etc.; R3 and R4 are H, (C1-C6)alkyl, (C3-C6)cycloalkyl, etc., or taken together form a (C3-C6)cycloalkyl), compositions thereof, and methods of use thereof. I are useful, in therapy, as agents against a host of diseases caused by and/or associated to a disregulated protein kinase activity and more particularly, Cdk2 and Cdc7 activity. I have protein kinase inhibiting activity and more particularly, Cdk2 and Cdc7 inhibiting activity; no biol. data is given in the patent. Example compound II was synthesized by cyclization of DL-2-(1-Amino-2-benzyloxyethyl)-5-(2-aminopyrimidin-4-yl)-1H-pyrrole-3-carboxylic acid. The experimental process involved the reaction of 1-(3-Fluoropyridin-4-yl)ethanol(cas: 87674-15-5).Quality Control of 1-(3-Fluoropyridin-4-yl)ethanol

The Article related to pyrrolopyrrolone preparation kinase inhibitor cancer other disease treatment, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Quality Control of 1-(3-Fluoropyridin-4-yl)ethanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On June 21, 2007, Vanotti, Ermes; Menichincheri, Maria; Orsini, Paolo; Scolaro, Alessandra; Varasi, Mario published a patent.Electric Literature of 87674-15-5 The title of the patent was Preparation of N-substituted pyrrolopyridinones active as kinase inhibitors. And the patent contained the following:

The title compounds I [A = pyridin-4-yl, 3-fluoropyridin-4-yl, 2-aminopyrimidin-4-yl; R1 = H, halo, alkyl; R2 = alkyl, cycloalkyl, aryl, etc.; R3-R6 = H, alkyl, aryl, etc.], useful as Cdk2 or Cdc7 antagonists, were prepared Thus, reacting tert-Bu 2-(2-aminopyrimidin-4-yl)-4-oxo-1,4,6,7-tetrahydropyrrolo[3,2-c]pyridine-5-carboxylate with 1-bromo-2-fluoroethane followed by deprotection afforded 2-(2-aminopyrimidin-4-yl)-1-(2-fluoroethyl)-1,5,6,7-tetrahydropyrrolo[3,2-c]pyridin-4-one. Pharmaceutical composition comprising the compound I is disclosed. The experimental process involved the reaction of 1-(3-Fluoropyridin-4-yl)ethanol(cas: 87674-15-5).Electric Literature of 87674-15-5

The Article related to pyrrolopyridinone preparation cdk2 cdc7 protein kinase inhibitor antagonist, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Electric Literature of 87674-15-5

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On January 6, 2011, Guzzo, Peter R.; Surman, Matthew David; Henderson, Alan John; Jiang, May Xiaowu published a patent.Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol The title of the patent was Preparation of azinone-substituted azapolycycles as MCH-1 receptor antagonists and use in the treatment of diseases. And the patent contained the following:

Title compounds I [R1 = H, (un)substituted alkyl, alkenyl, alkynyl, etc; R2 and R4 independently = H, CONH2 and derivatives, (un)substituted alkyl, aryl, etc.; R2 and R3 or R3 and R4 taken together to form an (un)substituted 3- to 7-membered heterocycle; at least one of R2 and R3 or R3 and R4 taken together to form an (un)substituted 3- to 7-membered heterocycle; each R5 independently = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc.; R6 = H, halo, (un)substituted aryl, heteroaryl, etc.; A = (CH2)m; B = (un)substituted aryl, heteroaryl, cycloalkyl, etc.; D = (CH2)n; L = (CH2)pO, (CH2)p, CH=CH, or bond; X = CR12, C(R12)2, N, or NR12; Y = CR12, C, or N; Z = CH, C, or N; R12 = H, halo, NH2 and derivatives, (un)substituted alkyl, aryl, etc.; m and n = 0 or 1, wherein m + n = 1; p = 1 to 4; q = 0 to 3; dash bond represents an optional double bound], and their pharmaceutically acceptable salts, oxides, solvates, or prodrugs, are prepared and disclosed as MCH-1 receptor antagonists and useful in the treatment of obesity, anxiety, depression, non-alc. fatty liver disease, and psychiatric disorders. Thus, e.g., II·HCl was prepared by acylation of 2-(6-bromo-1-methyl-1H-indol-3-yl)ethanamine with 4-bromobutyryl chloride followed by intramol. cyclization, intramol. reductive N-alkylation, amination with 4-(benzyloxy)pyridin-2(1H)-one, and addition of hydrochloric acid. Select I were evaluated for their MCH-1 antagonistic activity, e.g., II·HCl demonstrated a Ki value of 14.9 nM. The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol

The Article related to azinone azapolycycle preparation mch receptor antagonist treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Name: (6-(Trifluoromethyl)pyridin-3-yl)methanol

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On July 3, 2008, Ibrahim, Prabha N.; Bremer, Ryan; Zhang, Chao; Zhang, Jiazhong; Hirth, Klaus-Peter; Wu, Guoxian; Zhu, Hongyao published a patent.Application of 386704-04-7 The title of the patent was Pyrrolo[2,3-b]pyridine compounds and methods for kinase modulation, preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds of formula I, which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Compounds of formula I wherein n is 0, 1, 2 and 3; Z2 is N and CR12; Z6 is CR16; L4 is (CR10R11)p-X-(CR10R11)q; X is O, S, NH and derivatives, CO, CS, SO, SO2, CONH and derivatives, CSNH and derivatives, NHCO and derivatives, etc.; p and q are independently 0, 1 and 2, provides that at least one of p and 1 is 0; R4, R5, R6, R11, R15, R16 and R60 is H, halo, (un)substituted lower alkyl, (un)substituted lower alkenyl, (un)substituted lower alkynyl, (un)substituted (hetero)cycloalkyl, (un)substituted (hetero)aryl, etc.; R61 is H and lower (fluoro)alkyl; A is O, S, CH2, CHOH, CHNH2, CF2, CHF, NH and derivatives, CO, CS, SO, SO2, etc.; R10 and R11 and independently H, F and (un)substituted lower alkyl; R17 is H, halo, (un)substituted lower alkyl, OH and derivatives; and their salts, prodrugs, tautomers and isomers thereof, are claimed. Example compound II was prepared by benzylation of 4-hydroxy-3-methoxybenzaldehyde with 4-chlorobenzyl bromide; the resulting 4-(4-chlorobenzyloxy)-3-methoxybenzaldehyde underwent addition of 7-azaindole to give 3-((4-(4-chlorobenzyloxy)-3-methoxyphenyl)(methoxy)methyl)-1H-pyrrolo[2,3-b]pyridine, which underwent demethoxylation to give compound II. All the invention compounds were evaluated for their protein kinase modulatory activity (some data given). The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Application of 386704-04-7

The Article related to pyrrolopyridine preparation protein kinase modulator treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Application of 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts

On July 3, 2008, Ibrahim, Prabha N.; Bremer, Ryan; Zhang, Chao; Zhang, Jiazhong; Hirth, Klaus-Peter; Wu, Guoxian; Zhu, Hongyao published a patent.Recommanded Product: 386704-04-7 The title of the patent was Pyrrolo[2,3-]pyridine compounds and methods for kinase modulation, preparation, pharmaceutical compositions and use in the treatment of diseases. And the patent contained the following:

Compounds of formula I, which are active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Compounds of formula I wherein A1 is O, CR40R41, CO and NH and derivatives; Z2 is N and CR56; Z6 is N and CR52; L3 is NH and derivatives, S, O, CONH and derivatives, NHCO and derivatives, etc.; R40, R41, R52 and R56 are independently H, F, lower (fluoro)alkyl, lower (fluoro)alkoxy, lower (fluoro)alkylthio, etc.; R61 is H, and lower (fluoro)alkyl; R100 and R101 are independently H, OH, NH2, CN, CO2H, NO2, SO2NH2, CONH2, etc.; R53 and R55 are independently H, halo, (un)substituted lower alkyl and (un)substituted lower alkoxy; n is 0, 1, 2 and 3; and their salts, prodrugs, tautomers, and isomers thereof, are claimed. Example compound II was prepared by addition of 7-azaindole to 4-(4-chlorobenzyloxy)-3-fluorobenzaldehyde; the resulting [4-(4-chlorobenzyloxy)-3-fluorophenyl]-(1H-pyrrolo[2,3-b]pyridin-3-yl)methanol underwent oxidation to give compound II. All the invention compounds were evaluated for their protein kinase modulatory activity (some data given). The experimental process involved the reaction of (6-(Trifluoromethyl)pyridin-3-yl)methanol(cas: 386704-04-7).Recommanded Product: 386704-04-7

The Article related to pyrrolopyridine preparation protein kinase modulator treatment disease, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Recommanded Product: 386704-04-7

Referemce:
Alcohol – Wikipedia,
Alcohols – Chemistry LibreTexts